New group of potential diabetes drugs with fewer side effects can reprogram insulin-resistant cells to be healthier

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...
Business Wire

DPP-IV Inhibitors Edge Ahead of PPAR-Gamma Agonists in Patient Share Among Newly Diagnosed Type 2 Diabetes Patients

EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...
BioWorld

Novel PPAR system agonist shows promise in metabolic syndrome treatment

Researchers from Guandong Pharmaceutical University reported on the synthesis and preclinical characterization of a series of novel long-acting peroxisome proliferator-activated receptor (PPAR) ...
Medscape

Promising Topline Phase 2 Results for Novel Oral Alzheimer's Drug

T3D-959, an oral dual delta/gamma peroxisome proliferator-activated nuclear receptor (PPAR) agonist, has shown promise in a phase 2 randomized, placebo-controlled study of adults with mild-to-moderate ...